AbbVie Inc., ABBV is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, AbbVie Inc., ABBV has a market cap of 102589.28. Since its IPO date on the 1/2/2013, AbbVie Inc., ABBV performance year to date is 10.49%. Today AbbVie Inc., ABBV has gained 0.45%, with a current price of 64.45.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 71.00%. The management of the company have seen the company have a payout ratio of 64.30%. Return of assets are at 10.20%, with return on investment at 16.90%.
In terms of debt levels and profit levels, AbbVie Inc., ABBV is seeing a long-term debt/equity of 6.35. While Total debt/equity is 6.87. With a profit margin of 23.00%, this is combined with a gross margin of 79.80%, and operating margin of 34.20%. AbbVie Inc. ability to meet debt levels, with a current ratio of 1.6, while the quick ratio is 1.4.
For the last year AbbVie Inc., ABBV has seen a EPS growth of 185.20%. A performance for the year of -2.09%. The 52-week high is -7.32%, and the 52-week low is 44.67%. The average volume for AbbVie Inc., ABBV is 2397.
With a target price of 70, can AbbVie Inc., ABBV reach this target? Looking at the value indicators of AbbVie Inc., ABBV. AbbVie Inc. has a P/E of 19.22 and a forward P/E of 11.43. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.17. AbbVie Inc. also has a P/S and a P/B of 4.31 and 22.36 respectively. For P/cash, AbbVie Inc. has a value of 11.93, while it is 24.79 for P/free cash flow.
At the current price of 64.45, AbbVie Inc. has a dividend yield of 3.55%. We see a return on equity of 115.60%.
Looking more long-term AbbVie Inc., is projected to get an EPS growth for the next five years of 16.39%. In the short-term an EPS growth of 17.87% in the next year is forecasted. This is after a EPS growth of 185.20% for this year and for the last five years a 3.50% growth has been seen.